R&D channel feed

Struc­ture’s oral GLP-1 a ‘work in progress’ fol­low­ing Phase IIa obe­si­ty and di­a­betes da­ta

Last year

Bris­tol My­ers cuts PhI­II PD-1/LAG-3 tri­al in col­orec­tal can­cer short af­ter drug com­bo fails analy­sis

Last year
Pharma

Ex­clu­sive: A long­time VC takes on his own rare dis­ease as Sanofi, Boehringer com­mit $80M to launch new plat­form study

Last year

Re­neo’s PhI­Ib rare dis­ease tri­al fail­ure forces lay­offs, cost cuts — stock plum­mets

Last year

Jay Brad­ner joins Am­gen to lead R&D as David Reese moves to new chief tech­nol­o­gy of­fi­cer role

Last year
People

Head­ed to San Fran­cis­co? Here’s how you can cus­tomize your ex­pe­ri­ence at #JPM24 with End­points News

Last year
Bioregnum

Mod­er­na, Mer­ck un­veil three-year mid-stage da­ta for vac­cine-Keytru­da com­bo in melanoma, with PhI­II un­der­way

Last year

Up­dat­ed: Ver­tex un­veils PhI­II plans for non-opi­oid drug fol­low­ing mid-stage suc­cess in pe­riph­er­al neu­ro­path­ic pain

Last year

Ex­clu­sive: Park­er In­sti­tute ex­pands to Weill Cor­nell Med­i­cine as it grows im­munother­a­py work

Last year

Cor­rect­ed: Dizal presents up­dat­ed PhII PT­CL da­ta, plans to file for ac­cel­er­at­ed ap­proval in the US next year

Last year

Bis­pecifics con­tin­ue im­pres­sive ef­fi­ca­cy streak, but com­pa­nies look to re­duce side ef­fects: #ASH23

Last year

J&J and Gen­mab tout first-line in­jectable Darza­lex for mul­ti­ple myelo­ma: #ASH23

Last year

FDA sets late 2024 de­ci­sion dead­line for Pfiz­er’s 'pan-he­mo­phil­i­a' drug: #ASH23

Last year
FDA+

Bris­tol My­ers bags Sys­tIm­mune’s lung can­cer drug for $800M up­front in its third ADC-fo­cused pact of 2023

Last year
Deals

Biotech CAR-T roundup: Au­to­lus, Gra­cell tout ear­ly-stage da­ta at #ASH23

Last year
Cell/Gene Tx

Bris­tol My­ers and 2sev­en­ty bio's Abec­ma sur­vival da­ta raise ques­tions ahead of FDA’s ad­vi­so­ry com­mit­tee meet­ing: #ASH23

Last year

Bi­par­ti­san House bill seeks to boost pe­di­atric drug de­vel­op­ment via new FDA penal­ties for non­com­pli­ance

Last year
Pharma
FDA+

Af­ter two his­toric ap­provals, Ed­i­tas un­veils promis­ing ear­ly re­sults for its sick­le cell ther­a­py: #ASH23

Last year

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel pre­dic­tions

Last year
People
AI

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

Last year
Cell/Gene Tx

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

Last year
Cell/Gene Tx

Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

Last year
Cell/Gene Tx

Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Last year
Pharma

Roche touts full da­ta for drug in first-line PIK3CA-mu­tat­ed breast can­cer

Last year
First page Previous page 57585960616263 Next page Last page
A service from the Financial Times